Clinical trials: Rheumatoid Arthritis
Rheumatoid Arthritis
A Drug Use Investigation of ENBREL for Post-marketing Surveillance (PMS) for RA and PsA
The objective of this investigation is to identify the following problems and questions with respect to the safety and efficacy of Enbrel during the post-marketing period as required by Korea Food and Drug Administration (KFDA)'s…
- Trial name
- NCT00195403
- Testing
- Etanercept
- Where
- 4 sites in South Korea
- Volunteers
- 1,014 people
- Sponsor
- Pfizer
Rheumatoid Arthritis
A Study of Tocilizumab as Monotherapy or in Combination With DMARDs in Patients With Moderate to Severe Active Rheumatoid Arthritis
This open-label single-arm study will evaluate the safety, tolerability and efficacy of tocilizumab [RoActemra/Actemra] in patients with moderate to severe rheumatoid arthritis who experience an inadequate clinical response to a…
- Trial name
- NCT01089023
- Testing
- tocilizumab [RoActemra/Actemra]
- Where
- 9 sites in Bahrain, Iran and 3 more
- Volunteers
- 95 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
GP2013 in the Treatment of RA Patients Refractory to or Intolerant of Standard Therapy
The purpose of this study is to determine the PK/PD, efficacy and safety of GP2013 in patients with severe rheumatoid arthritis.
- Trial name
- NCT01274182
- Testing
- GP2013, MabThera, Rituxan
- Where
- 57 sites in United States, Argentina and 12 more
- Volunteers
- 312 people
- Sponsor
- Sandoz
Rheumatoid Arthritis
A Non-Comparative Study to Assess the Safety of MabThera (Rituximab) in Patients With Rheumatoid Arthritis.
This single arm study will assess the safety of MabThera plus methotrexate in patients with rheumatoid arthritis who have had a lack of response to 1-5 DMARDs or biological agents.
- Trial name
- NCT00502996
- Testing
- Methotrexate, rituximab [MabThera/Rituxan]
- Where
- 49 sites in Argentina, Brazil and 8 more
- Volunteers
- 246 people
- Sponsor
- Hoffmann-La Roche
Systemic Lupus Erythematosus, Rheumatoid Arthritis
Safety and Tolerability Study Of PF-06835375 In Subjects With Seropositive Systemic Lupus Erythematosus Or Rheumatoid Arthritis
This is a Phase 1 single and multiple dose escalation study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06835375 in subjects with seropositive SLE or RA.
- Trial name
- NCT03334851
- Testing
- PF-06835375
- Where
- 17 sites in United States
- Volunteers
- 74 people
- Sponsor
- Pfizer
Rheumatoid Arthritis
A Study of MabThera (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-TNF Therapies.
This single arm study will evaluate the efficacy and safety of MabThera in combination with methotrexate in patients with rheumatoid arthritis who have had an inadequate response to one or more anti-TNF therapies.
- Trial name
- NCT00462345
- Testing
- rituximab, Methotrexate, Corticosteroid or NSAID
- Where
- 4 sites in South Korea
- Volunteers
- 40 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
A Study Comparing SB5 to Humira® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy
This is a randomised, double-blind, parallel group, multicentre clinical study to evaluate the efficacy, safety, tolerability, pharmacokinetics and immunogenicity of SB5 compared to Humira® in subjects with moderate to severe RA…
- Trial name
- NCT02167139
- Testing
- Humira (adalimumab), SB5 (proposed biosimilar to adalimumab)
- Where
- 2 sites in Lithuania, Poland
- Volunteers
- 544 people
- Sponsor
- Samsung Bioepis Co., Ltd.
Systemic Juvenile Idiopathic Arthritis
Single-dose Study to Assess Efficacy of Canakinumab (ACZ885) in Patients With Active Juvenile Idiopathic Arthritis (SJIA)
This study assessed the initial efficacy and safety of canakinumab over a 4 week period in patients with systemic juvenile idiopathic arthritis (SJIA) having a flare.
- Trial name
- β-SPECIFIC 1 (NCT00886769)
- Testing
- Canakinumab
- Where
- 91 sites in United States, Argentina and 20 more
- Volunteers
- 84 people
- Sponsor
- Novartis Pharmaceuticals
Rheumatoid Arthritis
Open Label Extension for Patients Coming From the Dosing Flexibility Study in Patients With Rheumatoid Arthritis (RA)
The purpose of this study is to continue to assess the safety of certolizumab pegol in combination with methotrexate (MTX).
- Trial name
- Dose Flex II (NCT00753454)
- Testing
- Certolizumab pegol
- Where
- 40 sites in United States, Canada
- Volunteers
- 168 people
- Sponsor
- UCB Pharma
Rheumatoid Arthritis
Efficacy and Safety of Adalimumab in Patients With Active Rheumatoid Arthritis Treated Concomitantly With Methotrexate.
The purpose of the study was to assess the safety, immunogenicity, and clinical efficacy of adalimumab compared with placebo (during double-blind phase) and to to evaluate the long-term safety and maintenance of efficacy…
- Trial name
- NCT00195702
- Testing
- Adalimumab
- Where
- 87 sites in United States, Canada
- Volunteers
- 619 people
- Sponsor
- Abbott
Arthritis, Rheumatoid
Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic (cs)/Biologic (b) Disease Modifying Anti-rheumatic Drugs (DMARDs)
This study [contRAst 2 (201791: NCT03970837)] is a phase 3, randomized, multicenter, double blind study to assess the safety and efficacy of GSK3196165 in combination with csDMARD(s), for the treatment of adult participants with…
- Trial name
- contRAst 2 (NCT03970837)
- Testing
- GSK3196165 (Otilimab), Tofacitinib
- Where
- 269 sites in United States, Argentina and 16 more
- Volunteers
- 1,764 people
- Sponsor
- GlaxoSmithKline
Rheumatoid Arthritis
Study To Assess The Efficacy And Safety Of Pf-06651600 In Subjects With Rheumatoid Arthritis With An Inadequate Response To Methotrexate
This is an 8 week study to assess the efficacy and safety profile of PF-06651600 in seropositive subjects with rheumatoid arthritis with an inadequate response to methotrexate (up to approximately 50% of subjects may also have…
- Trial name
- NCT02969044
- Testing
- PF-06651600
- Where
- 30 sites in United States, Bulgaria and 7 more
- Volunteers
- 70 people
- Sponsor
- Pfizer
Arthritis, Rheumatoid
Evaluation of Pharmacokinetics and Safety of GSK3196165 in Combination With Methotrexate in Japanese Subjects With Rheumatoid Arthritis
This is a randomized, double-blind, parallel group, 3 dosage level, placebo-controlled, Phase 1/2 study designed to evaluate the pharmacokinetics, safety, tolerability, and efficacy of the monoclonal antibody GSK3196165, in…
- Trial name
- NCT03028467
- Testing
- GSK3196165 Dose 1, GSK3196165 Dose 2, GSK3196165 Dose 3
- Where
- 32 sites in Japan
- Volunteers
- 15 people
- Sponsor
- GlaxoSmithKline
Arthritis, Rheumatoid
Long-term Safety and Efficacy of Sirukumab in Participants With RA Completing Studies CNTO136ARA3002 or CNTO136ARA3003
The purpose of this study is to evaluate the long-term safety and efficacy of CNTO 136 (sirukumab) in participants with rheumatoid arthritis (RA) who are unresponsive to treatment with modifying antirheumatic drugs (DMARDs) or…
- Trial name
- SIRROUND-LTE (NCT01856309)
- Testing
- Sirukumab 100 mg, Sirukumab 50 mg
- Where
- 197 sites in United States, Argentina and 27 more
- Volunteers
- 1,820 people
- Sponsor
- Janssen Research & Development, LLC
Arthritis, Rheumatoid
A Pilot Study of the Feasibility of Discontinuation of Adalimumab in Stable Rheumatoid Arthritis Patients in Clinical Remission
The purpose of this pilot study is to investigate the possibility of discontinuing adalimumab therapy in patients with rheumatoid arthritis who are in stable remission after treatment with adalimumab in combination with…
- Trial name
- ADMIRE (NCT00808509)
- Testing
- adalimumab, methotrexate
- Where
- 8 sites in Sweden
- Volunteers
- 33 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Rheumatoid Arthritis
A Phase III Transition Study of DRL Rituximab to Reference Medicinal Products
The objective of the current study is to assess the immunogenicity and safety of transitioning subjects with RA to DRL_RI from US-rituximab/EU-rituximab to continued treatment with US-rituximab/EU-rituximab.
- Trial name
- RI-01-007 (NCT04268771)
- Testing
- Experimental: Arm A: DRL_RI, Arm B: Rituxan®/Mabthera®
- Where
- 26 sites in United States
- Volunteers
- 140 people
- Sponsor
- Dr. Reddy's Laboratories Limited
Rheumatoid Arthritis
An Open-label Study With Tocilizumab in Patients With Rheumatoid Arthritis in a Local Environment
This open-label, multi-center study in a local environment will evaluate the safety and the effect on disease activity with regard to reduction in signs and symptoms over 6 months of treatment in patients with moderate to severe…
- Trial name
- NCT01254331
- Testing
- tocilizumab [RoActemra]
- Where
- 6 sites in Tunisia
- Volunteers
- 51 people
- Sponsor
- Hoffmann-La Roche
Keratoconus, Ocular Surface Disease
Pilot Study to Investigate the Feasibility, Reliability and Efficacy of Utilizing OCT to Automate PROSE Fitting
EYEdeal Scanning Technology enables rapid measurement of corneal and scleral topography. By accurately measuring the ocular surface with this imaging technology, the current iterative fitting method required to fit PROSE…
- Conditions
- Keratoconus, Ocular Surface Disease, Pellucid Marginal Corneal Degeneration, Ectasia
- Trial name
- NCT04649177
- Testing
- Ocular surface optical coherence tomography
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Boston Sight
Rheumatoid Arthritis
MSB11456 in Participants With Moderately to Severely Active Rheumatoid Arthritis
The purpose of the study is to compare the efficacy, safety and immunogenicity of MSB11456 and EU approved RoActemra® in participants with moderately to severely active rheumatoid arthritis.
- Trial name
- NCT04512001
- Testing
- MSB11456, EU-approved RoActemra
- Where
- 85 sites in Bulgaria, Czechia and 7 more
- Volunteers
- 604 people
- Sponsor
- Fresenius Kabi SwissBioSim GmbH
Rheumatoid Arthritis
A Study of ARRY-438162 in Patients With Rheumatoid Arthritis
This is a Phase 2 study, involving a 12-week treatment period, designed to evaluate the effectiveness of investigational study drug ARRY-438162 in treating rheumatoid arthritis in patients on stable doses of methotrexate, and to…
- Trial name
- NCT00650767
- Testing
- ARRY-438162, MEK inhibitor; oral
- Where
- 35 sites in United States, Argentina and 5 more
- Volunteers
- 201 people
- Sponsor
- Array Biopharma, now a wholly owned subsidiary of Pfizer